A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Phase 2
Recruiting
- Conditions
- NeuroblastomaNeuroectodermal TumorsNeoplasms
- Interventions
- Drug: 131I-MIBG
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Jubilant DraxImage Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03561259
- Locations
- ๐บ๐ธ
University of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธUniversity of Wisconsin, American Family Children's Hospital and Clinical Science Center, Madison, Wisconsin, United States
๐บ๐ธChildren's Hospital Colorado, Aurora, Colorado, United States
Expanded Access Protocol Using 131I-MIBG
- Conditions
- NeuroblastomaParagangliomaPheochromocytoma
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Jubilant DraxImage Inc.
- Registration Number
- NCT01590680
- Locations
- ๐บ๐ธ
Children's Hospital Colorado, Aurora, Colorado, United States
๐บ๐ธChildren's Healthcare of Atlanta, Atlanta, Georgia, United States
๐บ๐ธSeattle Children's Hospital, Seattle, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath